Yancopoulos and Baras discussed Regeneron’s growth, notable drugs in the company’s portfolio, the success of the Regeneron Genetics Center, and new technologies that will change the face of drug development over the next decade or so, such as RNAi and CRISPR . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Close to the Edge: Regeneron’s George Yancopoulos and Aris Baras Discuss Company, COVID-19 appeared first on GEN – Genetic Engineering and Biotechnology News.
